A movement to promote and conduct research on the treatment and prevention of drug-resistant tuberculosis, with a commitment to address the substantial existing gaps in our knowledge and to help provide access to an effective cure and prophylaxis of drug-resistant tuberculosis throughout the world.
Nearly nine million people will develop tuberculosis (TB) in the world this year; at least 500,000 of these cases will have multidrug-resistant tuberculosis (MDR-TB). Some will receive treatment. However, we know little about the best ways of treating drug-resistant TB (DR-TB) and preventing tuberculosis in people who come in contact with DR-TB patients. Lacking a strong scientific basis in prescribing treatment regimens, existing TB treatments are often ineffective. TB control efforts require new evidence-based knowledge about optimal treatment regimens, prophylaxis, and, possibly, regimens involving new TB drugs, in order to address the growing health threats of MDR-TB and extensively drug-resistant (XDR) TB.
Click here to read a recent International Union Against Tuberculosis and Lung Disease Editorial by RESIST-TB members, Sarah McAnaw, Carole Mitnick, and Bob Horsburgh.
“New treatments for a serious disease generate understandable excitement among patients with life-threatening conditions. As pharmaceutical companies consider compassionate use of experimental drugs, one factor is commonly cited as a barrier to such use: fear that adverse events incurred by patients during Compassionate Use/Expanded Access (CU/EA) will impede regulatory approval of the drug. Such concerns stem from the obligation to report adverse events—that are serious, unexpected, and suspected to be related to the investigational drug— experienced by patients during treatment under CU/ EA programs.1 Such reports, it is feared, will damage the future of the drug, particularly since adverse events may not be related to the experimental drug and patients taking such drugs are typically sicker than the average patient.2 Existing evidence, however, does not support the notion that such events jeopardize regulatory approval.” Click here to read the article in full.
Recent News and Announcements
RESIST-TB invites you to register for TAG, TB CAB, and DR-TB STAT’s webinar on Implementing a bed aquiline-based, injectable free regimen for drug-resistant tuberculosis. On August 1, 2018 at 10AM EST, these organizations will host a critical discussion led by Dr. Nobert Ndejka from the National Department of Health in South Africa about roll-out of […]
Please join us this Thursday, July 12, 2018 from 09:30 – 11:00 EDT (15:30 – 17:00 CEST) for an exciting webinar presented by the endTB team, BDQ- and DLM-containing multidrug-regimens achieve excellent interim treatment response without safety concerns. This webinar will be presented by Drs. Molly Franke (Partners in Health), Cathy Hewison (Médecins Sans Frontières) and Palwasha Khan (Interactive […]
RESIST-TB invites you to join an exciting discussion on July 10, 2018 from 7-10 am EST as TREAT TB hosts a webinar on Challenges with MDR-TB Clinical Trial Implementation- Sponsor and Site Perspectives. This is the first in a series of webinars by TREAT TB to address challenges with implementing clinical trials of new treatments for MDR-TB in […]
South Africa’s department of health on Monday became the first one in the world to announce rolling out a new and much more tolerable drug to fight multidrug-resistant tuberculosis (MDR-TB). South Africa was the first to take this “positive step” towards making sure nobody would be denied access to the most suitable drug. Up until now‚ […]
The Union and RESIST-TB invite you to join an exciting webinar on Thursday, June 7th from 08:00 – 09:00 EST (14:00 – 15:00 CET and SAST) to review the results of the 2017-2018 DR-TB Working Group Survey regarding the global rollout of the 9-month TB regimen and the use of bedaquiline and delamanid for MDR-TB […]